Company news

Vertex Pharmaceuticals Incorporated news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older Who Have at Least One F508del Mutation

June 18, 2021

Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older Who Have at Least One F508del Mutation

June 17, 2021

Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting

June 10, 2021

Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency

June 9, 2021

CORRECTING and REPLACING Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations

June 8, 2021

Vertex Reports First-Quarter 2021 Financial Results

April 28, 2021

Vertex Announces European Commission Approval for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Cystic Fibrosis Patients 12 Years and Older With At Least One F508del Mutation in the CFTR gene

April 27, 2021

Vertex Announces NaV1.8 Inhibitor Advancing to Phase 2 Clinical Development

April 25, 2021

Vertex to Announce First-Quarter 2021 Financial Results on April 29

April 18, 2021

Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis With At Least One F508del Mutation

March 25, 2021

Vertex Receives Australian TGA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat People With Cystic Fibrosis Ages 12 Years and Older Who Have At Least One F508del Mutation

March 23, 2021

Vertex Announces FDA Fast Track Designation and Initiation of a Phase 1/2 Clinical Trial for VX-880, a Novel Investigational Cell Therapy for the Treatment of Type 1 Diabetes

March 9, 2021

Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results

January 31, 2021

Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (T1D)

January 27, 2021

Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations

January 25, 2021

Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1

January 21, 2021

Vertex Announces New Drug Submission for Investigational Triple Combination Medicine for the Treatment of Cystic Fibrosis Has Been Accepted for Priority Review by Health Canada

December 27, 2020

Vertex Announces FDA Approvals of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor) for Use in People With CF With Certain Rare Mutations

December 20, 2020

Vertex Announces European Commission Approval for SYMKEVI® (tezacaftor/ivacaftor) With KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 6-11 Years

November 26, 2020

Vertex Recommends Rejection of ‘Mini-Tender’ Offer From TRC Capital Investment Corporation

November 12, 2020

Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With Cystic Fibrosis as Early as Four Months of Age

November 4, 2020

Vertex Reports Third-Quarter 2020 Financial Results

October 28, 2020

Vertex to Announce Third-Quarter 2020 Financial Results on October 29

October 18, 2020

Vertex Provides Update on its Clinical Programs Targeting Alpha-1 Antitrypsin Deficiency

October 13, 2020

Vertex Announces European Medicines Agency Type II Variation Marketing Authorization Application Validation for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination with ivacaftor in People with One Copy of the F508del Mutation

September 13, 2020

Vertex Announces Positive Phase 3 Study for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children Ages 6-11 Years With Cystic Fibrosis to Support Submissions for Global Regulatory Approvals

September 9, 2020

FDA Accepts Vertex’s Supplemental New Drug Applications for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor) for Additional CFTR Mutations

August 31, 2020

European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Cystic Fibrosis in People Ages 12 Years and Older

August 20, 2020

Vertex Reports Second-Quarter 2020 Financial Results

July 29, 2020

Positive Phase 3 Study Results for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older With Cystic Fibrosis Who Have One Copy of the F508del Mutation and One Gating or Residual Function Mutation

July 19, 2020

Vertex to Announce Second-Quarter 2020 Financial Results on July 30

July 15, 2020

Vertex Announces Expansion of Reimbursement Agreement With NHS England to Include KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With KALYDECO® (ivacaftor)

June 29, 2020

Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) for Children and Adolescents With Cystic Fibrosis Between the Ages of 6 Months and 18 Years With the R117H Mutation in the CFTR Gene

June 9, 2020

Vertex Appoints Diana McKenzie to its Board of Directors

June 2, 2020

Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) for Children and Adolescents With Cystic Fibrosis Between the Ages 6 Months and 18 Years With the R117H Mutation in the CFTR Gene

April 30, 2020

Vertex Reports First-Quarter 2020 Financial Results

April 28, 2020

Vertex Announces Virtual 2020 Annual Meeting and Internet Access to Proxy Materials

April 27, 2020

Vertex Pharmaceuticals and Affinia Therapeutics Establish Multi-Year Collaboration to Discover and Develop Novel AAV Capsids for Genetic Therapies

April 26, 2020

Vertex Announces Innovative Reimbursement Agreement in Switzerland for ORKAMBI® (lumacaftor/ivacaftor) and SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Cystic Fibrosis Patients

April 20, 2020

Vertex to Announce First-Quarter 2020 Financial Results on April 29

April 19, 2020

The Vertex Foundation Commits $5 Million to Support Global COVID-19 Pandemic Response

April 6, 2020

Vertex Confirms Supply Chain Continuity and Business Outlook for Its Cystic Fibrosis Medicines and Provides Initial Update on Development Programs

March 26, 2020

Vertex Announces Cancellation of its March 3 Presentation at the Cowen Health Care Conference

March 1, 2020

Vertex Announces Availability of Cystic Fibrosis Medicine KALYDECO® (ivacaftor) in New Zealand

February 24, 2020

Vertex Reports Full-Year and Fourth-Quarter 2019 Financial Results

January 29, 2020

Vertex to Announce Full-Year and Fourth-Quarter 2019 Financial Results on January 30

January 20, 2020

Vertex Confirms Northern Ireland Offer Accepted for Cystic Fibrosis Medicines

November 11, 2019

Vertex Reports Third-Quarter 2019 Financial Results

October 29, 2019

Vertex to Announce Third-Quarter 2019 Financial Results on October 30

October 20, 2019

Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Eligible Infants with Cystic Fibrosis as Early as 6 Months of Age

October 17, 2019

← Newer news releases · Older news releases →

Calls

The 5 newest of 32 calls. Every call is listed under its year.

Decks

The 5 newest of 20 decks. Every deck is listed under its year.